Invesco Ltd. Grows Stock Position in Collegium Pharmaceutical, Inc. (NASDAQ:COLL)

Invesco Ltd. increased its holdings in Collegium Pharmaceutical, Inc. (NASDAQ:COLL) by 19.5% in the 4th quarter, according to its most recent disclosure with the SEC. The firm owned 1,775,760 shares of the specialty pharmaceutical company’s stock after acquiring an additional 289,335 shares during the period. Invesco Ltd. owned approximately 5.51% of Collegium Pharmaceutical worth $50,876,000 at the end of the most recent quarter.

Other hedge funds also recently added to or reduced their stakes in the company. New Age Alpha Advisors LLC acquired a new position in shares of Collegium Pharmaceutical in the 4th quarter valued at $40,000. KBC Group NV lifted its position in Collegium Pharmaceutical by 72.5% in the fourth quarter. KBC Group NV now owns 2,336 shares of the specialty pharmaceutical company’s stock valued at $67,000 after buying an additional 982 shares during the last quarter. Nisa Investment Advisors LLC boosted its stake in Collegium Pharmaceutical by 14.5% during the fourth quarter. Nisa Investment Advisors LLC now owns 2,493 shares of the specialty pharmaceutical company’s stock worth $71,000 after buying an additional 316 shares during the period. China Universal Asset Management Co. Ltd. increased its position in shares of Collegium Pharmaceutical by 10.4% during the fourth quarter. China Universal Asset Management Co. Ltd. now owns 6,838 shares of the specialty pharmaceutical company’s stock valued at $196,000 after acquiring an additional 642 shares during the last quarter. Finally, Aigen Investment Management LP acquired a new stake in shares of Collegium Pharmaceutical during the fourth quarter valued at about $230,000.

Collegium Pharmaceutical Price Performance

COLL stock opened at $27.12 on Wednesday. The business’s 50-day moving average is $28.98 and its two-hundred day moving average is $31.44. The company has a debt-to-equity ratio of 3.43, a current ratio of 0.97 and a quick ratio of 0.88. The firm has a market capitalization of $871.42 million, a P/E ratio of 11.69 and a beta of 0.76. Collegium Pharmaceutical, Inc. has a 1 year low of $23.23 and a 1 year high of $42.29.

Collegium Pharmaceutical (NASDAQ:COLL) last issued its earnings results on Thursday, February 27th. The specialty pharmaceutical company reported $1.63 earnings per share for the quarter, beating the consensus estimate of $1.54 by $0.09. Collegium Pharmaceutical had a net margin of 14.78% and a return on equity of 104.67%. The firm had revenue of $181.95 million for the quarter, compared to analysts’ expectations of $179.68 million. Analysts anticipate that Collegium Pharmaceutical, Inc. will post 5.62 earnings per share for the current fiscal year.

Insider Buying and Selling

In other news, EVP Scott Dreyer sold 2,255 shares of the business’s stock in a transaction that occurred on Friday, March 14th. The shares were sold at an average price of $30.00, for a total transaction of $67,650.00. Following the completion of the sale, the executive vice president now owns 124,421 shares in the company, valued at approximately $3,732,630. The trade was a 1.78 % decrease in their position. The sale was disclosed in a filing with the Securities & Exchange Commission, which can be accessed through this link. Also, EVP Shirley R. Kuhlmann sold 40,000 shares of the stock in a transaction on Tuesday, March 4th. The shares were sold at an average price of $28.08, for a total transaction of $1,123,200.00. Following the completion of the transaction, the executive vice president now directly owns 154,204 shares in the company, valued at $4,330,048.32. This trade represents a 20.60 % decrease in their ownership of the stock. The disclosure for this sale can be found here. Over the last quarter, insiders sold 81,693 shares of company stock worth $2,334,994. Corporate insiders own 3.98% of the company’s stock.

Wall Street Analysts Forecast Growth

A number of brokerages have issued reports on COLL. HC Wainwright reissued a “buy” rating and issued a $50.00 target price on shares of Collegium Pharmaceutical in a research report on Monday, March 24th. Needham & Company LLC reissued a “buy” rating and set a $46.00 target price on shares of Collegium Pharmaceutical in a research note on Wednesday, April 9th. Piper Sandler dropped their target price on Collegium Pharmaceutical from $37.00 to $36.00 and set a “neutral” rating for the company in a research report on Tuesday, February 4th. Finally, StockNews.com raised shares of Collegium Pharmaceutical from a “buy” rating to a “strong-buy” rating in a research report on Friday, April 11th. One analyst has rated the stock with a hold rating, four have assigned a buy rating and one has issued a strong buy rating to the company. According to data from MarketBeat, Collegium Pharmaceutical presently has a consensus rating of “Buy” and an average target price of $43.60.

Collegium Pharmaceutical Profile

Collegium Pharmaceutical, Inc, a specialty pharmaceutical company, engages in the development and commercialization of medicines for pain management. Its portfolio includes Xtampza ER, an abuse-deterrent, extended-release, and oral formulation of oxycodone for the management of pain severe enough to require daily, around-the-clock, long-term opioid treatment; Nucynta ER and Nucynta IR, which are extended-release and immediate-release formulations of tapentadol, indicated for the management of acute, severe, and persistent pain; Belbuca, a buccal film that contains buprenorphine; and Symproic, an oral formulation of naldemedine for the treatment of opioid-induced constipation in adult patients with chronic non-cancer pain.